• Nanion Technologies: イオンチャネル研究のスマートツール

    Nanion Technologies: イオンチャネル研究のスマートツール

  • SyncroPatch 384i: HTS Automated Patch Clamp

    SyncroPatch 384i: HTS Automated Patch Clamp

  • SURFE²R 96SE: ラベルフリーのトランスポーターHTS

    SURFE²R 96SE: ラベルフリーのトランスポーターHTS

  • Dynamic Clamp: Patchliner

    Dynamic Clamp: Patchliner

  • 脂質二分子膜実験: Orbitシリーズ

    脂質二分子膜実験: Orbitシリーズ

  • CardioExcyte 96 SOL: 心筋の光ペーシング

    CardioExcyte 96 SOL: 心筋の光ペーシング

Our Product Portfolio

SyncroPatch 384i

SyncroPatch 384i

Patchliner

Patchliner

Port-a-Patch

Port-a-Patch

Port-a-Patch mini

Port-a-Patch mini

CardioExcyte 96

CardioExcyte 96

FLEXcyte 96

FLEXcyte 96

SURFE²R 96SE

SURFE²R 96SE

SURFE²R N1

SURFE²R N1

Orbit 16

Orbit 16

Orbit Mini

Orbit Mini

Vesicle Prep Pro

Vesicle Prep Pro

CytoSwitch - "Inducing cell death using a photostatin on the CardioExcyte 96 and SOL"

Icon CE   CardioExcyte 96 and SOL Application Note   logo pdf   (0.4 MB)
Cells were kindly provided by LMU Munich/CytoSwitch.

 Summary:

Microtubules are important for cell support, acting as a kind of internal scaffold providing both shapeand an organized structure. Another important role of microtubules is the formation of the mitotic spindle which is critical in cell division. For this reason,compounds which control microtubule dynamics such as Taxol and Vinca alkaloids are important as anti-cancer therapeutics and biological research tools. Other compounds e.g. combretastin A-4 (CA4), have been shown to be powerful inhibitors of tubule polymerization. Until now, the use of such compounds in both biological research and as anti-cancer agentshas been limited because of their non-specificity; their bioactivity cannot be spatially or temporally directed,e.g. against particular tissues or cells. As an anti-cancer agent, CA4 was taken into Phase III clinical trials but was discontinued due to the cardio- or neurotoxic side effects at high doses as healthy organs were affected. The use of light to control the activity of microtubule inhibitors may offer a solution to combat the specificity problem by controlling the activation of the compound using visible light in a spatial, temporal and reversible fashion. The CytoSwitch startup project at the LMU Munich is developing photostatins as anti-cancer agents with reduced side-effects. Furthermore, CytoSwitch will commercialize photostatins as research tools for biological research.

Back

 

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.